

Global BD



Jørund Sollid, PhD

Global Lead, Neuroscience & Immuno-Inflammation BD
Mobile: +33 765 76 66 59 / jorund.sollid@servier.com

R&D External Innovation



Isabelle Dupin-Roger, PharmD

Director of External Innovation, Neuroscience & Immuno-Inflammation R&D
Mobile: +33 6 87 25 03 73 / isabelle.dupin-roger@servier.com

Local BD



USA

Pat Fetaya, MBA, MSc

Head, US Business Development, Servier Pharmaceuticals, USA
Mobile: +1.609.285.8275 / pat.fetaya@servier.com



Asia

Cynthia Wang, MBA, MSc

Director, Global Business Development, Asia-Pacific region
Mobile: +86 13910100149 / cynthia.wang@servier.com

Global BD Coordination



Bénédicte Barrault

GBD Coordination Officer, Neuroscience & Immuno-Inflammation
benedicte.barrault@servier.com

Immuno-Inflammation



Partnering **Interests**

Pre-clinical and early clinical stage

Indications

- Autoantibody-driven autoimmune diseases
- And other diseases sharing similar pathophysiological mechanisms

Biological mechanisms

Our discovery and research efforts are focused on connecting these indications with targets and biological pathways linked to auto-antibodies, auto-reactive B and T cells, antibody mediated pathways.

Modalities

- Small molecules
- Antibodies, Bispecifics, ADCs, Fusion proteins
- Oligonucleotides, ASO

Active Partnerships



Partnering with Servier

Partnership is embedded in our culture with highly engaged and diverse teams partnering for a shared purpose - contributing to therapeutic progress to serve patient needs. Our partnership approach serves one goal: to bring life-changing treatments to patients faster. We strive to always put patients first, leading to better outcomes for ourselves and our partners.



A partner of choice

A partner with strong commitment

Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier long-term vision applies to its partnership philosophy.

A partner with a global presence

With €4.7Bn of revenue in 2021 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China.

A partner with proven expertise and experience

Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners.

A partner you can rely on

Servier is proud of what has been achieved with its partners so far. Servier has a strong track record of providing flexible partnership structures to its many partners, as well as an R&D infrastructure with 2,900 people in France, Hungary and Boston and an extensive commercial knowledge of global markets.

Partnering interests



Oncology

Discovery & Early Clinical Focus

Cancer cell Targeting

- Synthetic lethality
- Apoptosis
- Precision oncology
- Epigenetic regulators

Modalities

- Small molecules

Late-stage Clinical Focus

- Hematologic tumors (NHL, ALL, AML)

Immuno-oncology

- Tumor micro-environment
- T cell targeting

- Antibodies, Bispecifics, ADCs

- Solid tumors; GI as a priority



Immuno-inflammation

- Autoantibody-driven autoimmune diseases
- And other diseases sharing similar pathophysiological mechanisms

Modalities

- Small molecules
- Antibodies, Bispecifics, ADCs, Fusion proteins
- Oligonucleotides, ASO



Neuroscience

- Hereditary forms of Parkinson Disease
- Rare neurological disorders including:
 - Multiple System Atrophy
 - Familial Amyotrophic Lateral Sclerosis
 - Spinocerebellar Ataxia
 - Progressive Supranuclear Palsy
 - Genetically driven paediatric epilepsias

Modalities

- Small molecules
- Oligonucleotides, ASO



Cardiovascular & Metabolism diseases

Acquire or license market-ready or mature assets for some geographies